Navigation Links
Southern Research Institute Names Blaine Knight Vice President of Drug Discovery
Date:2/14/2008

ior to joining Glaxo, Dr. Knight held several positions from 1987-1992 at Merck/MSDRL, most recently as the head of the Dept. of Enzymology.

He earned his Bachelor's degree in Chemistry from the University of Virginia in Charlottesville, and his Doctorate in Biochemistry from the University of Maryland in College Park. He completed his post-doctoral training at the University of Wisconsin in Madison.

Dr. Knight holds six patents, has authored or co-authored 53 scientific publications: and, as an invited speaker, has delivered 25 scientific presentations. He is a member of the American Chemical Society, the American Society of Biological Chemists and Molecular Biologists and the American Association for the Advancement of Science. He earned an American Heart Association Fellowship (Maryland Chapter) and a National Research Service Award from the Institute of General Medical Sciences.

About Southern Research Institute

Southern Research is an independent 501(c) 3, not-for-profit center for scientific research. Founded in 1941, Southern Research is known for innovative leadership in preclinical drug discovery and development, environment and energy research, and aerospace and materials engineering. Public and private sector clients include the National Institutes of Health: the U.S. Departments of Justice, Defense, and Energy; the Environmental Protection Agency: and NASA, as well as major private and public companies in the pharmaceutical, biotechnology, energy, manufacturing, and transportation industries. For more information visit http://www.SouthernResearch.org.

CONTACT:

Rhonda Jung

Southern Research, 205-581-2317, jung@southernresearch.org

Risa Burgess

Schwartz Communications, 781-684-0770, southern@schwartz-pr.com


'/>"/>
SOURCE Southern Research Institute
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Scientists puzzled by severe allergic reaction to cancer drug in the middle Southern US
2. USAID Assistant Administrator Hess Travels to Southern Africa
3. Southern Research Institutes Neurodegenerative Disease Drug Discovery Program Receives National Institute of Mental Health Funding
4. MIT Holding, Inc. signs partnership agreement with Georgia Southern University
5. Angel Flight West Recognizes Southern California Pilots at 24th Anniversary
6. Southern California Wildfires Continue to Threaten Residential Areas
7. NuVasive Cancels 10/24/07 Investor Reception Due to Concerns Over Southern California Fires
8. VA Remains Open for Care for Southern California Vets
9. Red Cross Receives $250,000 From Wal-Mart to Assist With Southern California Wildfire Relief Efforts
10. The Salvation Army Responds to Immediate Needs of Survivors and Relief Workers in Southern California Wildfires
11. CNA/NNOC Nurse Volunteers Deployed to Southern California Firestorm
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2009)... factor, researchers say , , SUNDAY, Dec. 6 (HealthDay ... the main tumor to other parts of the body ... which may prove a promising target for new drugs ... Previous studies have shown that TGFb (transforming growth factor ... new study, a team from Cancer Research UK used ...
(Date:12/6/2009)... Researchers find signs of feline DNA in virus , , SUNDAY, ... that causes AIDS might be found in a tiger that ... , It appears the virus took on a bit ... of that cat remains in the virus to this day. ... off an evolution of the virus that ultimately led to ...
(Date:12/6/2009)... the Medical College of Wisconsin, in Milwaukee, found a ... sickle cell disease complications in children. Barriers to its ... were also identified. The study led by Amanda ... the Medical College and Children,s Research Institute at the ... American Society of Hematology meeting Dec. 7, 2009, in ...
(Date:12/6/2009)... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... 2b 003-A1 study, known as the 003 trial, ... relapsed and refractory multiple myeloma patients. These data ... at the 51st annual meeting of the American ... in this trial is complete (n=269), and full ...
(Date:12/6/2009)... cell disease, a condition characterized by deformed and ... most common genetic blood disorders affecting millions of ... Americans.(1) Research presented today at the 51st Annual ... intriguing studies on the acute danger that the ... disorder, evaluations of both new and standard treatments ...
Breaking Medicine News(10 mins):Health News:Breast Cancer's Spread Now Better Understood 2Health News:AIDS May Date Back to Ancient Tiger 2Health News:New study finds barriers to pain treatment in children with sickle cell disease 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 2Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 3Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 4Health News:Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 2Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 3Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 4Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 5Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 6Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 7Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 8Health News:Studies Investigate Emerging Trends and Treatment Options for Patients With Sickle Cell Disease 9
... embolism can be identified through risk factors like blood pressure, age ... due to this factor // can be treated as outpatients, ... condition is due to an abrupt blockage of an artery due ... the US, this is a major health hazard. This is not ...
... from Johns Hopkins University School of Medicine as reported ... // that Antiretroviral combination drug of Tenofovir, Emtricitabine and ... load compared to most widely used drug combination Zidovudine, ... ‘study 934’ was conducted in 517 HIV patients from ...
... maternity care is expected, with a London- based NHS hospital ... pregnant women who pay ?4,000. The novel scheme would be ... ,The provision of such a cost-effective one-to-one service during ... impossible to reach due to high demand. However, it continues ...
... have now linked the liking of a taste to the brain ... blamed if you dislike the bitter gourd but just love the ... fruit fly Drosophila by Kristin Scott and colleagues. , ,According ... tastes. Multiple neurons interact in a way as to encode the ...
... Ministry source has revealed that the bird flu has claimed ... H5N1 virus in the country to 14.//The World Health Organization ... died last week in a West Java hospital. ... sister of theirs has also been hospitalized with the symptoms ...
... incidence of breast cancer in India is on the rise and ... cervical cancer to the second spot. The seriousness of the situation ... Medical Research (ICMR). // ,The rise is being ... that many cases in rural areas go unnoticed. It is reported ...
Other Medicine News:Health News:London Hospital Provides Specialized Care For Pregnant Women 2
(Date:12/6/2009)... FDA has approved new technology that now allows ... The SonoCine Automated Whole-breast Ultrasound Method and is ... - Arizona Breastnet, in Scottsdale. This unique technology ... tool to enhance yearly mammography screening. Until now, ... - not for screening for breast cancer. ,, ...
(Date:12/6/2009)... -- RNL Bio Co., Ltd, ( www.rnl.co.kr ) ... cell therapeutics announced today that a 46-year-old female, ... receiving stem cell treatment. Park was suffering from ... the central nervous system (brain and spinal cord). ... which the nerves of the central nervous system ...
(Date:12/4/2009)... 4 A new, $2.8 million, four-year federal grant ... of Medicine and their collaborators at Wake Forest University ... blood degrades over time and how to address the ... been associated with increased risk for cardiovascular events and ...
Breaking Medicine Technology:New FDA Approved Breast Cancer Screening Tool 2New FDA Approved Breast Cancer Screening Tool 3Multiple Sclerosis Patient Finds Hope Through Stem Cell Treatment 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 2NHLBI Grant Awarded to Wake Forest, Pitt to Improve Banked Blood 3New Option for Erasing Wrinkles 47913 1New Option for Erasing Wrinkles 47913 2New Option for Erasing Wrinkles 47913 3New Option for Erasing Wrinkles 47913 4LNA Based HIF 1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 12470 1LNA Based HIF 1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 12470 2LNA Based HIF 1 Alpha Inhibitor Shows Early Signs of Clinical Benefit 12470 3Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 1Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 2Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 3Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 4Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 5Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 6Cantel Medical Reports a 109 25 Increase in Net Income EPS of 240 25 vs 240 12 for Quarter Ended April 30 2009 47909 7
... after the identification of,the gene responsible for progeria, ... team of Spanish and French researchers (Carlos,Lopez-Otin and ... Levy and coll. -,Inserm/AP-HM, Marseille, France) have successfully ... treatment, combining two existing,pharmacological molecules, should slow down ...
... the, Anti-Tumor Activity of Bavituximab in Combination with Carboplatin and ... ... Peregrine,Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that patient screening,and dosing ... efficacy of bavituximab in combination with chemotherapy in patients,with non-small cell lung ...
Other Medicine Technology:Hope for Progeria - Successfully Validated on Mice, a Treatment Could Soon be Tested on Children 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 2Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 3Peregrine Pharmaceuticals Doses First Patient in Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer 4
... Only the Innova 3100 lets you ... one system. In one room. With no ... perfectly designed for a wide range of ... of view well suited for a variety ...
... as Antidiurectic Hormone (ADH), is synthesized in ... flow to the posterior pituitary for storage ... by changes in blood osmolality and also ... blood volume or arterial pressure. Non-osmotic stimuli ...
... identified in 1980 (1) and has only recently ... (2). PYY is produced by the gut and ... is found to decrease appetite. The main form ... is PYY3-36, the N-terminal truncated form of the ...
... secreted by the kidney, plays a ... The renin-angiotensin system regulates blood pressure, ... by the kidney. Renin is secreted ... decreased intravascular volume and decreased plasma ...
Medicine Products: